BB Biotech Posts CHF 605 Million Profit Amid Portfolio Expansion

The third quarter proved pivotal for the company, yielding US drug approvals for three portfolio members: Revolution Medicines for daraxonrasib, Scholar Rock Holding for apitegromab, and Regeneron for garetosmab. Beyond these regulatory wins, Amgen and Argenx delivered strong Phase III data, further cementing the innovation pipeline. These results highlight the firm's ability to identify high-potential drug developers in the US and Western Europe.

Corporate activity remained high as five portfolio companies were acquired throughout the year, including Crinetics Pharmaceuticals and Nuvalent in the third quarter alone. These transactions generated roughly CHF 280 million in proceeds, which the investment team promptly redeployed. The firm initiated twelve new positions, diversifying into commercial-stage businesses like Biogen and Incyte, while exiting eight others. Looking ahead, BB Biotech plans to capitalize on recent market corrections, targeting firms whose share prices have dipped despite stable clinical prospects. With additional regulatory decisions expected for Vertex Pharmaceuticals and BridgeBio Pharma before year-end, the firm maintains a long-term focus on balancing scientific potential against market risk.